Selpercatinib (Retevmo), a selective oral RET inhibitor, demonstrated durable antitumor activity and a manageable safety ...
Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and ...
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether ...
Elevar Therapeutics and Hengrui Pharma have resubmitted applications to the FDA seeking approval of rivoceranib plus ...
Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, ...
The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...
Mogamulizumab (Poteligeo) was associated with durable real-world treatment outcomes in patients with mycosis fungoides (MF) ...
Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of ...
The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival ...
Alicia Morgans, MD, explains how the ARACOG trial showed higher cognitive decline with enzalutamide vs darolutamide in ...
However, applying a conventional age-based testing threshold would have substantially reduced the number of patients identified. Restricting testing to patients diagnosed before age 50 would have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results